Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

The interactions of therapeutic antibodies with Fc receptors.

Albanesi M, Daƫron M.

Immunol Lett. 2012 Mar 30;143(1):20-7. Review.

PMID:
22553779
2.

T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.

Noy R, Eppel M, Haus-Cohen M, Klechevsky E, Mekler O, Michaeli Y, Denkberg G, Reiter Y.

Expert Rev Anticancer Ther. 2005 Jun;5(3):523-36. Review.

PMID:
16250828
3.

Bispecific antibodies targeting cancer cells.

Peipp M, Valerius T.

Biochem Soc Trans. 2002 Aug;30(4):507-11. Review.

PMID:
12196124
4.

Human antibody-Fc receptor interactions illuminated by crystal structures.

Woof JM, Burton DR.

Nat Rev Immunol. 2004 Feb;4(2):89-99. Review.

PMID:
15040582
5.

Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.

Denkberg G, Reiter Y.

Autoimmun Rev. 2006 Apr;5(4):252-7. Epub 2005 Aug 8. Review.

PMID:
16697965
6.

Fc receptors: role in biology and antibody therapy.

van de Winkel JG.

Immunol Lett. 2010 Jan 18;128(1):4-5. doi: 10.1016/j.imlet.2009.09.005. Epub 2009 Oct 4. Review.

PMID:
19808048
7.
8.

Antibodies, Fc receptors and cancer.

Nimmerjahn F, Ravetch JV.

Curr Opin Immunol. 2007 Apr;19(2):239-45. Epub 2007 Feb 8. Review.

PMID:
17291742
9.

Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity.

Clynes R.

Hematol Oncol Clin North Am. 2006 Jun;20(3):585-612. Review.

PMID:
16762726
10.

Possible applications of antibodies or their genes in cancer therapy.

Kuroki M, Huang J, Shibaguchi H, Tanaka T, Zhao J, Luo N, Hachimine K, Kinugasa T, Maekawa S, Enatsu S, Hamanaka W, Fukami T, Kuroki M.

Anticancer Res. 2006 Nov-Dec;26(6A):4019-25. Review.

11.

Fc receptors as targets for immunotherapy.

Rouard H, Tamasdan S, Moncuit J, Moutel S, Michon J, Fridman WH, Teillaud JL.

Int Rev Immunol. 1997;16(1-2):147-85. Review.

PMID:
9651790
12.

[Target antigens for therapeutic antibodies in oncology: many candidates, few successes].

Ceze N, Probst A, Lecomte T, Ohresser M, Paintaud G, Watier H.

Bull Cancer. 2007;94(7 Suppl):F129-36. Review. French.

PMID:
17964990
13.

Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone.

Marvin JS, Zhu Z.

Curr Opin Drug Discov Devel. 2006 Mar;9(2):184-93. Review.

PMID:
16566289
14.

[Development of effective antigen delivery carrier to dendritic cells via Fc receptor in cancer immunotherapy].

Suzuki R, Utoguchi N, Kawamura K, Kadowaki N, Okada N, Takizawa T, Uchiyama T, Maruyama K.

Yakugaku Zasshi. 2007 Feb;127(2):301-6. Review. Japanese.

15.

How antibodies work: focus on Fc receptors.

Metzger H, Kinet JP.

FASEB J. 1988 Jan;2(1):3-11. Review.

16.

Neutrophils in antibody-based immunotherapy of cancer.

van Egmond M.

Expert Opin Biol Ther. 2008 Jan;8(1):83-94. Review.

PMID:
18081538
17.

Antibody-Fc receptor interactions in protection against intracellular pathogens.

Joller N, Weber SS, Oxenius A.

Eur J Immunol. 2011 Apr;41(4):889-97. doi: 10.1002/eji.201041340. Epub 2011 Mar 17. Review.

18.

Targeted cellular immunotherapy with bifunctional antibodies.

Nelson H.

Cancer Cells. 1991 May;3(5):163-72. Review.

PMID:
1832553
19.

Antibodies and their fragments as anti-cancer agents.

Schaedel O, Reiter Y.

Curr Pharm Des. 2006;12(3):363-78. Review.

PMID:
16454750
20.

The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Sesarman A, Vidarsson G, Sitaru C.

Cell Mol Life Sci. 2010 Aug;67(15):2533-50. doi: 10.1007/s00018-010-0318-6. Epub 2010 Mar 9. Review.

PMID:
20217455
Items per page

Supplemental Content

Write to the Help Desk